Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors

Audio By Carbonatix

SAN DIEGO--(BUSINESS WIRE)--Oct 1, 2025--

Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced the appointment of Shalini Sharp, MBA, to its board of directors. A veteran biopharma finance executive, Ms. Sharp brings to Iambic decades of industry leadership, board service, strategic planning and capital markets experience.

“We are thrilled to have Shalini join the Iambic board as we scale our AI-driven pipeline and expand our business through strategic technology enablement agreements,” said Tom Miller, PhD., Iambic’s Co-Founder and Chief Executive Officer. “Her experience working with dynamic companies through key inflection points, from founding all the way through to global commercialization, will benefit our team as we look ahead to multiple near-term clinical and business milestones.”

Ms. Sharp currently holds several board and advisory roles with public and private life sciences companies. Prior to this, she was Chief Financial Officer and Executive Vice President at the rare disease company, Ultragenyx Pharmaceutical Inc. Previously, she was Chief Financial Officer and Vice President at the immuno-oncology biotechnology company, Agenus Inc. Her experience also includes roles at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs.

“Iambic continues to demonstrate the potential of its industry-leading AI platform with a proprietary pipeline of highly differentiated drug candidates, while its technology innovations also enable other biopharmaceutical companies to accelerate their pursuit of novel targets,” said Ms. Sharp. “I am excited to work with management as they build upon these successes and continue to transform the way that new treatments for patients are discovered and developed.”

Ms. Sharp’s current board roles include BeOne Medicines (formerly BeiGene), Neurocrine Biosciences, Organon & Co, Septerna Inc. and Mahzi Therapeutics (private). She previously served on the boards of Mirati Therapeutics, Sutro Biopharma, Precision Biosciences, Panacea Acquisition Corp., Array Biopharma, and Agenus Inc. She holds a B.A. and an MBA from Harvard University.

About Iambic’s AI-Driven Discovery Platform

The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

About Iambic Therapeutics

Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai

View source version on businesswire.com:https://www.businesswire.com/news/home/20251001729712/en/

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY PHARMACEUTICAL HEALTH ARTIFICIAL INTELLIGENCE TECHNOLOGY CLINICAL TRIALS

SOURCE: Iambic Therapeutics

Copyright Business Wire 2025.

PUB: 10/01/2025 09:00 AM/DISC: 10/01/2025 09:02 AM

http://www.businesswire.com/news/home/20251001729712/en